| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FAAH2 |
| Uniprot No | Q6GMR7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-532aa |
| 氨基酸序列 | MAPSFTARIQLFLLRALGFLIGLVGRAALVLGGPKFASKTPRPVTEPLLLLSGMQLAKLIRQRKVKCIDVVQAYINRIKDVNPMINGIVKYRFEEAMKEAHAVDQKLAEKQEDEATLENKWPFLGVPLTVKEAFQLQGMPNSSGLMNRRDAIAKTDATVVALLKGAGAIPLGITNCSELCMWYESSNKIYGRSNNPYDLQHIVGGSSGGEGCTLAAACSVIGVGSDIGGSIRMPAFFNGIFGHKPSPGVVPNKGQFPLAVGAQELFLCTGPMCRYAEDLAPMLKVMAGPGIKRLKLDTKVHLKDLKFYWMEHDGGSFLMSKVDQDLIMTQKKVVVHLETILGASVQHVKLKKMKYSFQLWIAMMSAKGHDGKEPVKFVDLLGDHGKHVSPLWELIKWCLGLSVYTIPSIGLALLEEKLRYSNEKYQKFKAVEESLRKELVDMLGDDGVFLYPSHPTVAPKHHVPLTRPFNFAYTGVFSALGLPVTQCPLGLNAKGLPLGIQVVAGPFNDHLTLAVAQYLEKTFGGWVCPGKF |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于 **FAAH2(脂肪酸酰胺水解酶2)重组蛋白** 的参考文献示例(内容基于模拟文献，可能需结合实际文献调整)：
---
1. **文献名称**: *"Cloning and Functional Characterization of Human FAAH2: A Comparative Study with FAAH1"*
**作者**: Wei, S. et al.
**摘要**: 本研究成功克隆并在哺乳动物细胞中表达了重组人源FAAH2蛋白，分析了其水解脂肪酸酰胺的活性。结果显示，FAAH2与FAAH1的底物偏好性不同，且在pH和温度敏感性上存在显著差异，提示二者在生理功能中的不同作用。
2. **文献名称**: *"Expression and Purification of Recombinant FAAH2 in E. coli for Structural Studies"*
**作者**: Patel, J. & Singh, R.
**摘要**: 报道了一种利用大肠杆菌表达系统高效制备重组FAAH2蛋白的方法，并通过亲和层析和尺寸排阻色谱纯化获得高纯度蛋白。研究进一步利用圆二色光谱验证了蛋白的正确折叠，为后续结构解析奠定基础。
3. **文献名称**: *"Role of FAAH2 in Endocannabinoid Metabolism: Insights from Recombinant Enzyme Assays"*
**作者**: Garcia, M. et al.
**摘要**: 通过体外重组FAAH2蛋白的酶活实验，发现其对油酰乙醇胺(OEA)和棕榈酰乙醇胺(PEA)的分解活性高于经典内源性大麻素(如AEA)，表明FAAH2可能在内源性脂质代谢中具有独特调控功能。
4. **文献名称**: *"Development of FAAH2-Specific Inhibitors Using Recombinant Protein-Based Screening"*
**作者**: Lee, H. et al.
**摘要**: 基于重组FAAH2蛋白的高通量筛选平台，鉴定出多个选择性抑制FAAH2(而非FAAH1)的小分子化合物，为靶向FAAH2的疾病治疗工具开发提供了潜在候选分子。
---
**注**：以上文献为模拟示例，实际引用请通过PubMed、Web of Science或Sci-Hub等平台检索真实文献(关键词：FAAH2. recombinant protein, expression, fatty acid amide hydrolase)。
Fatty acid amide hydrolase 2 (FAAH2) is a lesser-studied member of the serine hydrolase enzyme family, first identified in the early 2000s through genomic analyses. It shares partial homology with its well-characterized counterpart, FAAH1. which is known for hydrolyzing endocannabinoids like anandamide (AEA) and other bioactive lipid amides. However, FAAH2 exhibits distinct structural and functional features. Unlike FAAH1. which is broadly expressed in the nervous system and regulates neurotransmitter signaling, FAAH2 is primarily found in peripheral tissues, including the placenta, liver, and kidney, suggesting divergent physiological roles.
Recombinant FAAH2 protein is engineered for in vitro studies to explore its enzymatic activity, substrate specificity, and regulatory mechanisms. Research indicates FAAH2 prefers neutral pH environments and may localize to lysosomes or lipid droplets, contrasting with FAAH1’s endoplasmic reticulum association. Its substrates include oleamide and palmitoylethanolamide (PEA), implicating potential roles in lipid metabolism and inflammation modulation. Despite lower catalytic efficiency compared to FAAH1. FAAH2’s unique tissue distribution and substrate profile have sparked interest in its evolutionary significance and possible therapeutic applications. For instance, FAAH2 polymorphisms are linked to altered lipid signaling pathways in metabolic disorders.
The production of recombinant FAAH2 typically involves heterologous expression systems like E. coli or mammalian cells, enabling structural analysis (e.g., crystallography) and inhibitor screening. Such studies aim to develop isoform-specific drugs targeting endocannabinoid signaling without central nervous system side effects. Ongoing research seeks to clarify FAAH2’s biological relevance, particularly its interplay with FAAH1 and contribution to diseases like pain, neurodegeneration, or cancer. Despite progress, FAAH2 remains understudied, highlighting the need for further biochemical and physiological characterization.
×
